The novel lignan isochaihulactone inhibits cell proliferation and is an effective inducer of apoptosis in a variety of carcinoma cell lines. To determine the mechanisms underlying these effects, we examined isochaihulactone-induced changes in gene expression using oligodeoxynucleotide-based microarray screening of a human lung carcinoma cell line, A549. Isochaihulactone-inducible genes included the early growth response gene-1 (EGR-1) and nonsteroidal anti-inflammatory drug-activated gene (NAG-1). Isochaihulactone increased EGR-1 and then NAG-1 mRNA and protein expression. Pure isochaihulactone induced phosphorylation of extracellular signal-regulated kinase (ERK) 1/2. Isochaihulactone-induced increases in EGR-1 and NAG-1 expression were reduced by the mitogen-activated protein kinase kinase 1/2 inhibitor 2Ј-amino-3Ј-methoxyflavone (PD98059), and this effect was not blocked by the phosphatidylinositol 3-kinase/protein kinase B pathway inhibitor 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY294002). Inhibition of isochaihulactoneinduced NAG-1 expression by EGR-1 small interfering RNA blocked isochaihulactone-induced apoptosis in A549 cells, suggesting that induction of EGR-1 expression decreases survival of A549 cells. RNA interference using double-stranded RNA specific for NAG-1 also inhibited isochaihulactone-induced apoptosis, and cells transfected to increased NAG-1 expression had a greater apoptotic response to isochaihulactone and reduced colony formation efficiency. In addition, treatment of nude mice with isochaihulactone increased the in vivo NAG-1 expression as examined by immunohistochemistry from tumor biopsy. Isochaihulactone treatment increased the luciferase activity of NAG-1 in A549 cells transfected with the NAG-1 promoter construct. This induction increased expression of NAG-1 that was p53-independent and Sp1-dependent. Our findings suggest that NAG-1 expression is up-regulated by isochaihulactone through an ERK-dependent pathway involving the activation of EGR-1.
mulations such as Sho-Saiko-To-Tang (TJ9 in Japan) and Bu-Zhong-Yi-Qi-Tang. We previously reported that the crude acetone extract of B. scorzonerifolium causes cell cycle arrest of lung adenocarcinoma A549 cells in the G 2 /M phase, formation of giant cells, and apoptosis . The acetone extract fraction was further partitioned, and we identified a novel lignan, isochaihulactone, that has antitumoral activity against A549 cells in vitro and in vivo (Chen et al., 2006) . In previous articles, it has been reported that this compound was isolated from Bursera microphylla (Burseraceae), also with an antitumoral effect (Tomioka et al., 1986) . These findings indicate that isochaihulactone is a promising new antimitotic anticancer compound with potential for clinical applications.
To identify genes that are involved in isochaihulactone-induced growth arrest and apoptosis, we used oligodeoxynucleotide-based microarray screening. We found that several isochaihulactone-induced genes are early response genes such as early growth response gene-1 (EGR-1) (also known as NGFI-A, Krox24, TIS8, and Zif/268) . EGR-1 is a member of the zinc finger family of transcription factors and plays a role in cell growth and differentiation (Krishnaraju et al., 1995; Thiel and Cibelli, 2002) . EGR-1 has been reported to be regulated by numerous growth-regulated genes such as c-myc and transforming growth factor-␤ (TGF-␤), and to inhibit growth (Albo et al., 1994; Elkon et al., 2004) . Induction of EGR-1 expression by antitumorigenic compounds is known to involve members of the family of mitogen-activated protein kinases (MAPKs) or phosphatidylinositol-3-kinase (PI3K)-dependent pathways. For example, induction of EGR-1 expression by the peroxisome proliferator-activated receptor-␥ (PPAR␥) ligand troglitazone occurs by the ERK phosphorylation pathway rather than by the PPAR␥ pathway (Baek et al., , 2004b . In contrast, PPAR␥ ligands such as 1,1-bis(3Ј-indolyl)-1-(p-substituted phenyl)methane compounds induced EGR-1 through a PI3K-dependent pathway, which in turn activated serum-response elements in the EGR-1 promoter .
We also found that several isochaihulactone-induced genes are induced by nonsteroidal anti-inflammatory drugs (NSAIDs). NSAID-activated gene-1 (NAG-1) (also known as MIC-1, GDF-15, placental TGF-␤, and PLAB) was highly induced in our study. NAG-1 is a transforming growth factor-␤-like secreted protein. It was initially characterized as a p53-regulated gene Bottone et al., 2002; Wilson et al., 2003) . Overexpression of NAG-1 in breast cancer cells both in vitro and in vivo results in growth arrest and apoptosis; similar results were also observed for colon cancer cells (Baek et al., 2004a Eling et al., 2006) and for treatment of prostate cancer cells with purified NAG-1, which induced apoptosis (Liu et al., 2003) . These findings suggest that NAG-1 is linked to apoptosis and that reduced expression of NAG-1 may enhance tumorigenesis.
It is known that the PPAR␥-dependent activation of NAG-1 by troglitazone is due to induction of EGR-1, which in turn activates NAG-1 (Rokos and Ledwith, 1997; Baek et al., 2003 Baek et al., , 2004b Yamaguchi et al., 2006) . Like troglitazone, the PPAR␥-active 1,1-bis(3Ј-indolyl)-1-(p-substituted phenyl)methanes also induce EGR-1, which in turn interacts with proximal (GC-rich) EGR-1 motifs in the NAG-1 promoter (Chintharlapalli et al., 2005 (Chintharlapalli et al., , 2006 . This reaction represents a pathway for induction of EGR-1 and NAG-1, and these responses contribute to the induction of growth inhibition and apoptosis by antitumoral compounds in cancer cells.
During this investigation, we found that isochaihulactone induced growth inhibition and apoptosis by activating EGR-1 and NAG-1 through an ERK-dependent pathway and did not involve activation of PI3K signaling. NAG-1 induction after isochaihulactone treatment was followed by EGR-1 activation. Also, NAG-1 expression in the xenograft animal model was correlated with inhibition of tumor development. These results distinguish the mechanism of action of isochaihulactone from that of 1,1-bis(3Ј-indolyl)-1-(p-substituted phenyl) methanes and provide a model for understanding the downstream effectors for isochaihulactone-induced apoptosis in A549 cells. Thus, NAG-1 seems to exert its antitumoral activity in the tumor suppression pathway.
Materials and Methods
Fraction Purification of Isochaihulactone and Structure Determination. B. scorzonerifolium roots were supplied by ChungYuan Co. (Taipei, Taiwan, Republic of China), and the plant was identified by Professor Lin of the National Defense Medicinal Center, where a voucher specimen was deposited (NDMCP 900801). Isochaihulactone (4-benzo[1,3]dioxol-5-ylmethyl-3-(3,4,5-trimethoxyl-benzylidene)-dihydro-furan-2-one) was prepared as described previously (Chen et al., 2006) .
Chemicals and Reagents. RPMI 1640 medium, Eagle's minimum essential medium, fetal bovine serum (FBS), penicillin, streptomycin, trypsin/EDTA, and a NuPAGE Bis-Tris Electrophoresis System (precast polyacrylamide minigel) were purchased from Invitrogen (Carlsbad, CA). An RNA isolation kit was purchased from QIAGEN (Valencia, CA). Dimethyl sulfoxide (DMSO), 3-(4,5-dimethyl thizol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), the PKC inhibitor GF109203X, paclitaxel, and horseradish peroxidase-conjugated secondary antibodies were purchased from Sigma Chemical (St. Louis, MO). The ERK1/2 kinase inhibitor PD98059 and the JNK inhibitor SP600125 were purchased from R&D Systems (Minneapolis, MN). The p38 inhibitor SB203580 and the PI3K/AKT inhibitor LY294002 were purchased from Calbiochem (San Diego, CA). EGR-1 rabbit polyclonal antibody (1:1000) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). NAG-1/PTGF-␤ (1:1000) and phosphor-GSK-3␤ (1:1000) rabbit polyclonal antibodies were purchased from Upstate Biotechnology (Lake Placid, NY). Phosphor-AKT (1:1000), phosphor-ERK1/2 (1:2000), ERK1/2(1:1000), phosphor-p38 (1:1000), p38 (1:2000), phosphor-JNK1/2(1:2000), and JNK1/2(1:1000) monoclonal antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA). Mycoplasma removal reagent was from Dainippon Pharmaceutical Co. (Osaka, Japan). The annexin V-FLOUS Staining Kit was from Roche Molecular Biochemicals (Mannheim, Germany). Polyvinylidene difluoride membranes, a bovine serum albumin protein assay kit, and Western blot chemiluminescence reagent were purchased from Amersham Biosciences (Arlington Heights, IL).
Cell Lines and Culture. A549 human lung adenocarcinoma cells, H460 human lung large cell carcinoma cells, H1299, p53-null and p16-deficient human non-small cell carcinoma cells, and HT29 human colon adenocarcinoma cells were obtained from American Type Culture Collection (Manassas, VA). The HepG2 human hepatoma cell lines were kindly provided by M. J. Chou and C. S. Yang (Hosono et al., 1991) . A549, H460, H1299, and HT29 cancer cells were maintained with RPMI 1640 medium containing 10% FBS and 100 ng/ml each of penicillin and streptomycin at 37°C in a humidified atmosphere with 5% CO 2 . HepG2 cancer cells were maintained in Eagle's minimum essential medium with 10% FBS and 100 ng/ml each of penicillin and streptomycin at 37°C in a humidified atmosphere with 5% CO 2 . All cultures were free of Mycoplasma.
RNA Extraction and Expression Profiling. For microarray experiments, human lung carcinoma A549 cells were treated with 20
Isochaihulactone-Induced NAG-1 and Apoptosis in Lung Cancer M isochaihulactone for 3 and 48 h. RNA was extracted with TRIzol (Invitrogen) and then purified using RNeasy (QIAGEN), according to the manufacturer's specifications. RNA quality was assessed using either agarose gel electrophoresis or an Agilent Bioanalyzer. A total of 100 ng of total RNA was then amplified using the Affymetrix small sample protocol (GeneChip Eukaryotic Small Sample Target Labeling Technical Note), and 15 g of cRNA was then hybridized on each U133A GeneChip and scanned according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). Image files were processed using MAS 5.0 to produce CHP files. Images were masked to remove any streaks/smears present, and no scaling of data was performed during analysis. Data were then imported into GeneSpring (version 7.2; Silicon Genetics, Redwood City, CA) and per chip normalization was performed, using the 50.0th percentile of all measurements in that sample. Differential expressions of cDNA were confirmed by RT-PCR analysis.
RT-PCR Analysis. Total RNA from A549 cells was isolated as described above. cDNA was synthesized by reverse transcription of 2 g of total RNA using oligo(dT) [12] [13] [14] [15] [16] [17] [18] and SuperScript II RNA reverse transcriptase (Invitrogen). The cDNA was then used as the template to amplify the corresponding DNA fragments by PCR using two sets of synthetic oligonucleotide primers. DNA amplification was performed by PCR with the Thermocycler 2400 (PerkinElmer Life and Analytical Sciences, Boston, MA) using the following parameters: 35 cycles of denaturing at 95°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 2 min. Primers used for the PCR amplifications are listed in Table 1 . The PCR products were separated on 2% agarose gels, stained with ethidium bromide, and visualized using the FluorChem imaging system (Alpha InnoTech, San Leandro, CA), and levels of glyceraldehyde-3-phosphate dehydrogenase were used as the control.
Western Blot Analysis. Approximately 5 ϫ 10 6 cells were cultured in 100-mm 2 dishes and then incubated in various concentration of isochaihulactone for the indicated time. The cells were lysed on ice with 200 l of lysis buffer (50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM MgCl 2 , 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml pepstatin, and 50 g/ml leupeptin) and centrifuged at 13,000g for 20 min at 4°C. The protein concentrations in the supernatants were quantified using a bovine serum albumin protein assay kit. Electrophoresis was performed on a NuPAGE Bis-Tris Electrophoresis System using 50 g of reduced protein extract per lane. Resolved proteins were then transferred to polyvinylidene difluoride membranes. Filters were blocked with 5% nonfat milk overnight and probed with an appropriate dilution of primary antibodies for 1 h at room temperature. Membranes were washed three times with 0.1% Tween 20 and incubated with horseradish peroxidaseconjugated secondary antibody (1:5000) for 1 h at room temperature. All proteins were detected using Western Lightning Chemiluminescence Reagent Plus and quantified using a densitometer.
Growth Inhibition Assay. The viability of the cells after treatment with various chemicals was evaluated using an MTT assay preformed in triplicate. Briefly, the cancer cells (5 ϫ 10 3 ) were incubated in 96-well plates containing 200 l of serum-containing medium. Cells were permitted to adhere for 12 to 18 h and then were washed with phosphate-buffered saline (PBS). Solutions were always prepared fresh by dissolving 0.2% DMSO or drugs in culture medium and added to A549 cells. For inhibitor treatment experiments, cells were treated with 20 M isochaihulactone and preincubated for 1 h with 25 and 50 M ERK1/2 kinase inhibitor PD98059, 10 and 20 M PI3K inhibitor LY294002, or 10 and 20 M PKC inhibitor GF109203X. After 48 h of exposure, the drug-containing medium was removed, washed with PBS, and replaced by fresh medium. The cells in each well were then incubated in culture medium with 500 g/ml MTT for 4 h. After the medium were removed, 200 l of DMSO and 25 l of glycine buffer (0.1 M glycine and 0.1 M NaCl, pH 10.5) were added to each well. Absorbance at 570 nm of the maximum was detected by a PowerWave X Microplate ELISA Reader (Bio-Tek Instruments, Winooski, VT). The absorbance for DMSO-treated cells was considered as 100%. The results were determined by three independent experiments.
Detection of Apoptosis. Apoptosis was analyzed according to the method described by van Engeland et al. (1998) to detect the integrity of cellular membrane and the externalization of phosphatidylserine. In brief, approximately 10 6 cells were grown in 35-mm diameter plates. The cells were treated with various herbal extracts and chemicals according to the experimental design and then were labeled with 10 g/ml annexin V-FLOUS and 20 g/ml PI before harvesting. After labeling, the cells were washed with binding buffer and harvested by scraping. Cells were resuspended in binding buffer at a concentration of 2 ϫ 10 5 cells/ml before analysis by flow cytometry (FACScan). The data were analyzed with WinMDI V2.8 software. The percentage of cells undergoing apoptosis was determined by three independent experiments.
Transfection with siRNA. EGR-1 siRNA targeting the sequence AGA GGC AUA CCA AGA UCC A and NAG-1 siRNA targeting the sequence GAC UCC AGA UUC CGA GAG U were synthesized (Ambion, Austin, TX). Cells at 50 to 60% confluence were transfected using GeneJammer Transfection Reagent according to the manufacturer's protocol (Stratagene, La Jolla, CA) with EGR-1 or NAG-1 siRNA (Ambion) (in various concentrations of 10 -50 nM) for 48 h. Medium was removed, and the cells were treated with isochaihulactone or vehicle for up to 48 h. After incubation, RNA was isolated for RT-PCR, protein was isolated for Western blot analysis, and cells were collected for analysis of apoptosis.
In Vitro Transfection. The full-length NAG-1 cDNA containing the entire coding region was isolated by RT-PCR using two primers from the PTGFB sequence (GenBank accession no. AF008303): sense strand, 5Ј-ACCTGCACAGCCATGCCCGGGCA-3Ј; and antisense strand, 5Ј-CAGTGGAAGGACCAGGACTGCTC-3Ј. To create the pNAG-1-expressing A549 stable cell line, A549 was transfected with 2 g of pCDNA3.1-NAG-1 or pCDNA3.1-neoplasmids using GeneJammer reagent. After 48 h, the cells were subjected to selection for stable integrants by exposure to 500 g/ml G418 (Invitrogen) in complete medium containing 10% FBS for 3 weeks to select the transfected cells. The cells were then assessed for overexpression of NAG-1 by Western blot analysis.
Colony Formation Assay. NAG-1-transfected cells were plated onto 10-cm culture dishes with 500 cells/dish in 5 ml of RPMI 1640 in the presence or absence of isochaihulactone for 24 h. The cells were then cultured in fresh medium for 10 to 15 days. When the colonies became visible, they were stained with 2% methyl blue 
F, forward; R, reverse.
748
solution to assess the survival rate. Single colonies were selected and grown separately. The results were determined by three independent experiments. Construction of Plasmids. Human NAG-1 promoter was isolated from volunteer blood using a DNA extraction kit (QIAGEN) according to the manufacturer's protocol. The Ϫ499/ϩ70 (pNAG499/ ϩ70) and Ϫ137/ϩ70 (pNAG137/ϩ70) NAG-1 promoter regions were generated using the following two primers: pNAG499/ϩ70: sense, 5Ј-CGACGCGTCACCTCTCCAGTGAGAGTCTC-3Ј, and antisense, 5Ј-GGAAGATCTTGAGAGCCATTCACCGTCC-3Ј; pNAG137/ϩ70: sense, 5Ј-CGACGCGTTAAATACACCCCCAGACCCCG-3Ј, and antisense, 5Ј-GGAAGATCTTGAGAGCCATTCACCGTCC-3Ј. The amplified product was digested with MluI and BglII restriction enzymes and ligated into pGL3-basic luciferase vector (Promega, Madison, WI) digested with the same enzymes. The Sp1 binding site was mutated using the Quick Change site mutagenesis kit (Stratagene). For the point mutation of Sp1-BC sites on the Ϫ137/ϩ70 promoter region, the following primers were used: pNAG137mut: sense, 5Ј-GGAGTT-CGGGACTGAGCATTCGGAGACGGA-3Ј, and antisense, 5Ј-TCC-GTCTCCGAATGCTCAGTCCCGAACTCC-3Ј. Site-specific mutations were confirmed by DNA sequencing.
Transfection of the Luciferase Reporter System. A549 cells were plated in six-well plates at 2 ϫ 10 5 cells/well in RPMI 1640 medium supplemented with 10% fetal bovine serum. After growth overnight, plasmid mixtures containing 2 g of NAG-1 promoter linked to luciferase and 0.2 g of pRT-null (Promega) were transfected by GeneJammer reagent according to the manufacturer's protocol. After 48 h of transfection, the cells were harvested in 1ϫ luciferase lysis buffer, and luciferase activity was determined and normalized to the pRL-TK luciferase activity with a dual luciferase assay kit (Promega). For isochaihulactone treatment, the cells were treated with the drug in the absence of serum for 24 h and then assayed for luciferase activity. Cells were treated with 29 M sulindac sulfide for 24 h as a positive control. The results were determined by three independent experiments.
Antitumor Activity in Vivo. Xenograft mice were used as a model system to study the cytotoxicity effect of isochaihulactone in vivo; implantation of cancer cells was performed similarly to previous reports. Female congenital athymic BALB/c nude (nu/nu) mice were purchased from the National Sciences Council (Taipei, Taiwan), and all procedures were performed in compliance with the standard operating procedures of the Laboratory Animal Center of Tzu Chi University (Hualien, Taiwan). All experiments were carried out using 6-to 8-week-old mice weighing 18 to 22 g. The mice were implanted with 1 ϫ 10 7 cells s.c. into their backs. When the tumors reached 80 to 120 mm 3 in volume, animals were divided randomly into control and test groups consisting of six mice per group (day 0). Daily s.c. administration of isochaihulactone, dissolved in a vehicle of 20% Tween 80 in normal saline (v/v), was performed from days 0 to 4, far from the inoculated tumor sites (Ͼ1.5 cm). The control group was treated with vehicle only. The mice were weighed three times a week up to days 21 to 28 to monitor effects and at the same time the tumor volume was determined by measurement of the length (L) and width (W) of the tumor. The tumor volume at day n (TVn) was calculated as TV (cubic millimeters) ϭ (L ϫ W 2 )/ 2 . The relative tumor volume at day n (RTVn) versus that at day 0 was expressed according to the following formula: RTVn ϭ TVn/TV0. Tumor regression [T/C (percent)] in treated versus control mice was calculated using T/C (percent) ϭ (mean RTV of treated group)/(mean RTV of control group) ϫ 100. Xenograft tumors as well as other vital organs of treated and control mice were harvested and fixed in 4% formalin, embedded in paraffin, and cut in 4-mm sections for histologic study.
Immunohistochemical Staining. All tumor tissues (s.c. A549 tumors with or without isochaihulactone treatment) were fixed in 4% formalin at 4°C for 16 h and then embedded in paraffin. Paraffin sections (5 m) were deparaffinized in xylene and rehydrated through a graded series of ethanol solutions. The sections were incubated with blocking solution (5% milk powder and 1% bovine serum albumin in phosphate-buffered saline) for 60 min at room temperature, followed by a 4°C overnight incubation with anti-NAG-1/PTGF-␤ rabbit polyclonal antibody in blocking solution. Subsequently, the immune complexes were visualized using horseradish peroxidase-conjugated anti-goat IgG secondary antibodies (1:1000 dilution; Santa Cruz Biotechnology Inc.) and the LSAB2 system (Dako North America Inc., Carpinteria, CA), respectively, and then incubated for 10 min with 0.5 mg/ml diaminobenzidine and 0.03% (v/v) H 2 O 2 in PBS. Finally, sections were counterstained with hematoxylin, mounted, observed under a light microscope at magnifications of 400ϫ, and photographed.
Statistical Analysis. The data are shown as mean Ϯ S.D.. The statistical difference was analyzed using the Student's t test for normal distributed values and the nonparametric Mann-Whitney U test for values of non-normal distribution. Values of P Ͻ 0.05 were considered significant.
Results

Microarrays.
To obtain insight into the mechanism by which isochaihulactone induces growth inhibition and apoptosis, we used oligodeoxynucleotide-based microarray screening to identify isochaihulactone-induced changes in gene expression. Human non-small cell lung carcinoma A549 cells were treated with 20 M isochaihulactone. After 3-and 48-h incubations, RNA was extracted and used in microarray screening. Primers were designed for different genes. The sequence of primers is shown in Table 1 . Among the genes, EGR-1, NAG-1, NRG-1, FGF-2, FEM-1, and Cullin 5 expression were up-regulated time dependently. This result was also confirmed by RT-PCR (Fig. 1) . EGR-1 and NAG-1, two genes implicated in growth inhibition and apoptosis (Baek et al., 2004 Chintharlapalli et al., 2005; Lim et al., 2007) , were highly induced by drug treatment. We investigated these effects further.
Isochaihulactone Induced EGR-1 and NAG-1 Protein Expression. In our previous study, the IC50 for isochaihulactone was 20 M in A549 cells (Chen et al., 2006) , and this concentration was used in the current experiments. To evaluate whether EGR-1 is involved in the induction of NAG-1 expression by isochaihulactone in A549 cells, EGR-1 and NAG-1 protein expressions were determined by Western blot analysis. After various times of exposure of cells to isochaihulactone, both EGR-1 and NAG-1 expressions were up-regulated in a time-dependent manner. EGR-1 was significantly induced at 6 h, and this effect was maintained until 24 h. 
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NAG-1 expression occurred later, being highest at 48 h (Fig. 2A) .
The induction of NAG-1 was not limited to lung carcinoma A549 cells. Isochaihulactone increased the level of NAG-1 protein expression in other lung carcinoma cell lines including H460 and H1299 cells, in human colorectal carcinoma HT29 cells, and in human hepatocellular carcinoma HepG2 cells (Fig. 2, B and C) . Because H1299 is a p53-null cell and NAG-1 can be induced by isochaihulactone in this cell line, induction by isochaihulactone must be p53-independent (Fig. 2D) .
Isochaihulactone-Induced ERK1/2 Activation Followed by Growth Inhibition in A549 Cells. A role for MAPKs in the regulation of NAG-1 and NAG-1 as a novel downstream target of the PI3K/AKT/GSK-3␤ (PI3K/AKT) pathway has been reported in several studies (Yamaguchi et al., 2004) . To determine whether MAPKs, PKC, and PI3K/ AKT play a role in isochaihulactone-induced growth inhibition in A549 cells, cells were treated with isochaihulactone in the presence and absence of the MEK1/2 inhibitor PD98059, the PKC inhibitor GF109203X, or the PI3K/AKT inhibitor LY294002 (10 -50 M). Only PD98059 (Fig. 3A) abrogated isochaihulactone-induced growth inhibition in a concentration-dependent manner. We also found that isochaihulactone had no effect on the activation of PKC or AKT/GSK-3␤ (Fig. 3B) .
Furthermore, to determine which MAPK pathways had been involved, we evaluated the effect of isochaihulactone on ERK1/2, p38, and JNK1/2 activation. We found (Fig. 3C) only phosphorylation of ERK1/2 after exposure of A549 cells to isochaihulactone at 120 to 240 min. In contrast, isochaihulactone had no effect on the activation of p38 or phosphor-JNK. It has been reported that ERK1/2 activation maybe occur through PKC or PI3K/AKT signaling pathways during drug-induced growth inhibition . We found that isochaihulactone had no effect on the activation of PKC or AKT/GSK-3␤ (Fig. 3B) .
ERK1/2 Signaling Pathway Was Involved in Isochaihulactone-Induced EGR-1 and NAG-1 Expressions. To investigate a possible role for ERK1/2 in the regulation of EGR-1 and NAG-1, A549 cells were treated with isochaihulactone in the presence and absence of the MEK1/2 inhibitor PD98059 (25 and 50 M), the p38 inhibitor SB203580 (10 and 20 M), or the JNK1/2 inhibitor SP600125 (10 and 20 M). Using Western blot analysis, we found that inhibition of ERK1/2 expression with PD98059 reduced both EGR-1 and NAG-1 protein levels in a dosedependent manner after treatment with isochaihulactone in A549 cells (Fig. 3D) . In contrast, inhibition of JNK1/2 had little effect on the induction of NAG-1, whereas inhibition of p38 had no effect on either of the two genes. These observations suggest that activation of the ERK1/2 signaling pathway was involved in isochaihulactone-induced EGR-1 and NAG-1 expression.
Induction of NAG-1 Requires EGR-1 Activation and EGR-1 Is Involved in Isochaihulactone-Induced Apoptosis. We determined whether EGR-1 is critical in the induction of NAG-1. The suppression of EGR-1 by EGR-1 siRNA (siEGR-1) or NAG-1 by NAG-1 siRNA (siNAG-1) in a concentration-dependent manner was confirmed by RT-PCR and Western blot analysis (Fig. 4, A and B) . To further characterize the role of EGR-1 in isochaihulactone-induced growth inhibition, flow cytometry analysis was performed to identify the percentage of apoptotic cells after treatment of EGR-1 with siRNA. Between 20 and 40% of apoptosis was inhibited by 20 and 50 nM EGR-1 siRNA after exposure of cells to 20 M isochaihulactone (Fig. 4C) . NAG-1 siRNA decreased apoptosis 12 to 35% (Fig. 4D) . To evaluate the significance of EGR-1 to the induction of NAG-1, cells were transiently transfected with siEGR-1 and subsequently treated with isochaihulactone. EGR-1 siRNA significantly blocked NAG-1 mRNA and protein expression induced by isochaihulactone, whereas NAG-1 siRNA had no obviously 
750
inhibitory effect on EGR-1 mRNA and protein expression (Fig. 4, E and F) . NAG-1 Enhances Isochaihulactone-Induced Apoptosis. NSAIDs induce apoptosis in colorectal cancer cells Baek et al., 2004a; Rosetti et al., 2006) . In our study, A549 cells were stably transfected with an expression vector containing the full-length NAG-1 coding region in the sense orientation. A pooled population of cells obtained after selection with G418 was then used. Western blot analysis indicated that these cells express NAG-1 protein at a 2.0-fold greater rate than do vector-transfected cells (Fig. 5A) . These stably transfected cells were incubated with isochaihulactone for 48 h, and apoptosis was again determined by flow cytometry. A higher percentage of pCDNA3.1-NAG-1 transfected cells than vectortransfected cells underwent apoptosis (Fig. 5B) . A colony formation assay also confirmed the fact that overexpression of NAG-1 enhanced isochaihulactone toxicity. In the presence of 20 M isochaihulactone, NAG-1 overexpression resulted in a significant reduction (ϳ70%) of the clonogenic capacity of A549 cells (Fig. 5C) .
Isochaihulactone Induced NAG-1 Expression. The region Ϫ73 to Ϫ51 of the NAG-1 promoter contains two Sp1 sites (Sp1-B and Sp1-C), which play a pivotal role in basal gene expression (Baek et al., 2001a (Baek et al., , 2004b . In addition, these Sp1-B and Sp1-C sites overlap with putative EGR-1 binding sites. To evaluate the importance of cis-acting elements regulating isochaihulactone-induced NAG-1 expression, two deletion NAG-1 promoter constructs, pNAG499/ϩ70 and pNAG137/ϩ70, were generated (Fig. 6A) . These constructs were transfected into A549 cells, which were then treated with vehicle or isochaihulactone for 24 h. As an internal control, the plasmid pRL-TK was used for adjusting transfection efficiency. As shown in Fig. 6B , isochaihulactone treatment resulted in a 7.5-to 5.0-fold induction of luciferase activity in pNAG499/ϩ70 and pNAG137/ϩ70 transfected cells. As a control, pGLBasic promoterless vector was transfected, and no increase in luciferase activity was found in the presence of isochaihulactone. To demonstrate the importance of Sp1 in isochaihulactone-induced NAG-1 expression, we performed mutational analysis of Sp1 sites. Sp1-BC sites were point-mutated using a site-directed mutagenesis kit (Fig. 6A) , and the constructs with mutational Sp1 sites resulted in a significant reduction of luciferase activity (ϳ80%) compared with wild-type constructs (Fig. 6B) . In addition, isochaihulactone did not induce pNAG137/ϩ70 construct promoter activity in the presence of the MAPK inhibitor PD98059 (Fig. 6C ). This result suggested that both Sp1 and EGR-1 may be involved in isochaihulactone-induced NAG-1 expression.
Isochaihulactone Blocks Tumor Growth in Vivo by Induction of NAG-1. The antitumor effect of isochaihulactone on A549 tumor cells may depend in part on NAG-1 expression. Human lung cancer xenografts were estab-20 M isochaihulactone for the indicated times. Total ERK1/2, phosphor-ERK1/2 (pERK1/2), total p38, phosphor-p38 (pp38), total JNK, and phosphor-JNK (pJNK)were detected by Western blot. D, Western blot of A549 cells pretreated with the MEK1/2 inhibitor PD98059 (25 and 50 M), the p38 inhibitor SB203580 (10 and 20 M), or the JNK1/2 inhibitor SP600125 (10 and 20 M) for 1 h and then treated with 20 M isochaihulactone for 24 h. 
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lished by s.c. injection of approximately 1 ϫ 10 7 A549 cells on the backs of nude mice. After the tumor reached approximately 80 to 120 mm 3 in size, mice were randomized into vehicle control and treatment groups (six animals each) and given a daily s.c. injection of either 0 (control group) or 50 mg/kg isochaihulactone (treatment groups) for 5 successive days. The median tumor size was effectively decreased by up to 80% after treatment with isochaihulactone (Fig. 7A) . To examine the inhibition of tumor growth with NAG-1 expression, samples of the tumors were removed by a knife at 35 days after initiation of drug treatment. The immunohistochemistry results showed increased NAG-1 protein expression in tumor cells relative to that the control group in vivo (Fig. 7, C and D) . The body weight of the tumor-bearing mice treated with 50 mg/kg was not obviously changed (Fig. 7B) . 
Discussion
In this study, oligodeoxynucleotide-based microarray analysis was used to investigate isochaihulactone-induced genes encoding proteins involving cell growth and apoptosis. Analysis with the Affymetrix Human Genome-U133 Plus 2.0 GeneChip identified more than 100 genes that were upregulated or down-regulated by isochaihulactone treatment. We then tested 6 of these genes in validation experiments using quantitative RT-PCR. Some of the genes up-regulated by isochaihulactone represent immediate-early response genes and genes induced by NSAIDs (Table 2) . We focused on Mutated base pairs are indicated in each mutated sequence. B, wildtype (pNAG137/ϩ70 and pNAG499/ϩ70) or Sp1/EGR-1 mutant vector (pNAG137mut) and pRL-TK cotransfected into A549 cells. These indicated promoter regions were fused to a luciferase report gene. Each construct (2 g) was cotransfected with 0.2 g of pRL-TK vector into A549 cells using GeneJammmer transfection reagent followed by treatment with 20 M isochaihulactone for 24 h. Cells were lysed, and luciferase activity was measured. Transfection efficiency for luciferase activity was normalized to Renilla luciferase (pRL-TK vector) . The x-axis shows relative luciferase units (RLU) (firefly luciferase/Renilla luciferase). C, NGA-1 promoter activity is attenuated by PD98059. A549 cells were transfected with pNAG137/ϩ70 reporter plasmid and pRL-TK plasmid. Forty-eight hours after transfection, cells were pretreated with PD98059 for 1 h and then treated with isochaihulactone for another 24 h. pNAG137/ϩ70 promoter construct activity was normalized to Renilla luciferase (pRL-TK vector). The data represent the means Ϯ S.D. of three different experiments. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001 versus vehicle.
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NAG-1. NAG-1 is a target gene for NSAIDs, and a unique member of the transforming growth factor-␤ superfamily. Increases in NAG-1 expression result in the induction of apoptosis in several cancer cell lines Baek et al., 2005) . Also, NAG-1 expression is induced not only by NSAIDs but also by several antitumorigenic compounds. These include dietary compounds, peroxisome proliferatoractivated receptor-␥ ligands, and phytochemicals (Baek et al., 2001b; Yamaguchi et al., 2006; Joshua et al., 2007) as well as resveratrol, genistein, diallyldisulfide, 5F203, and retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (Newman et al., 2003; Lee et al., 2005; Eling et al., 2006) . To determine whether NSAIDs induce expression of the NAG-1 protein, A549 tumor cells were treated with isochaihulactone or sulindac sulfide, a cyclooxygenase inhibitor, and Western blot analysis was performed. As shown in Fig.  2A , isochaihulactone time-dependently induced NAG-1 protein expression. By using colony formation assays and transfection viability assays, we showed that isochaihulactone induced growth arrest and apoptosis in A549 cells through the up-regulation of the antitumorigenic protein NAG-1 (Fig.  5C ). Furthermore, we had confirmed the antitumoral effect of isochaihulactone in our previously study (Chen et al., 2006) , and here we extended the inhibition of tumor growth based on NAG-1 protein expression in a nude mice xenograft animal model (Fig. 7, C and Fig. D) . These data indicate that the expression of NAG-1 is an essential factor in the antitumoral activity of isochaihulactone. In addition, by using an siRNA technique, our experiments also support the idea that NAG-1 expression has an apoptosis-promoting effect by silencing NAG-1 expression (Fig. 4D) . Finally, because the up-regulation of NAG-1 by isochaihulactone is followed by up-regulation of EGR-1, the silencing of EGR-1 expression by siRNAs could also inhibit NAG-1 RNA and protein expression (Fig.  4E) . In this examination, we found that NAG-1 siRNA would not affect levels of EGR-1 mRNA and protein expression (Fig.  4F) . In summary, we found that isochaihulactone increased EGR-1 expression, suggesting that the antitumor effect of isochaihulactone is mediated via this tumor suppressor protein. NAG-1 appears to be a key downstream target of EGR-1.
To determine which MAPK family is involved in the major signaling pathway for isochaihulactone-mediated NAG-1 upregulation and growth inhibition, MAPK inhibitors were applied to study the growth inhibition induced by isochaihulactone. In our study, PD98059 significantly decreased the growth inhibition induced by isochaihulactone (Fig. 3A) , but neither the p38 inhibitor SB203580 or the JNK inhibitor SP600125 could reverse isochaihulactone-induced growth inhibition (data not shown). Furthermore, only the MEK1/2 inhibitor PD98059 reduced isochaihulactone-induced EGR-1 and NAG-1 protein expression (Fig. 3D ). These data support the idea that isochaihulactone-induced ERK1/2 activity is critical in regulating EGR-1 and NAG-1 expression. In a report by Baek et al. (2004) , it was shown that a PI3K/AKT/GSK3␤ pathway regulates NAG-1 expression in human colorectal cancer cells as assessed by the inhibition of PI3K, AKT, and GSK-3␤. PI3K inhibition by LY294002 showed an increase in NAG-1 protein and mRNA expression, and 1L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-Ooctadecylcarbonate (an AKT inhibitor) also induced NAG-1 expression (Yamaguchi et al., 2004; Shim and Eling, 2005; Martinez et al., 2006; Pang et al., 2007) . In an attempt to identify the signaling pathway through which PI3K/AKT/ GSK3␤ is involved in receptor signal transduction through tyrosine kinase receptors for isochaihulactone, the effect of LY294002, a PI3K inhibitor, was examined. We found that LY294002 did not reverse tumor growth inhibition caused by isochaihulactone (Fig. 3A) . Compared with the effects of other phytochemical agents, this result suggests that the ability of our drug to cause tumor apoptosis might not go through this pathway.
By using a gel retardation method, many researchers have shown that EGR-1 protein binds to the NAG-1 promoter and trans-activates NAG-1 expression by competing against Sp1 and NAB1/2 transcription factors (Baek et al., 2001 ). The NAG-1 promoter (Ϫ1739 to ϩ 70) containing two p53 motifs and the Sp1 motifs were also present. Several dietary compounds induced NAG-1 expression by increasing p53 expression (Fu et al., 2002; Lim et al., 2007) . However, mutations commonly occur at the p53 tumor suppressor locus in many forms of cancer, including colorectal cancer. The increase in NAG-1 expression due to NSAIDs is independent of p53, suggesting that NSAIDs can still increase NAG-1 expression in tumors with p53 mutations. To determine whether p53 is the target motif of isochaihulactone, we used the p53-null cell line H1299. We found that even H1299 cells show NAG-1 expression that is induced by isochaihulactone (Fig. 2D ). This result indicates that the expressions of NAG-1 and of the p53 motif are independent.
Because we already excluded the idea that p53 has a required role in isochaihulactone effects on the NAG promoter, we explored the possible regulatory role of two Sp1s on the NAG-1 promoter. With our NAG-1 promoter, which contained two Sp1 motifs with an engineered luciferase reporter, isochaihulactone induced a 5.0 to 7.5-fold increase in luciferase activity compared with vehicle (Fig. 6B) . To further test whether these two Sp1 motifs were isochaihulactone functional motifs, mutation of the two Sp1 DNA sequences was done. Isochaihulactone did not increase reporter gene expression (Fig. 6B) . Together, these result indicate that isochaihulactone is associated with the Sp1 site rather than with p53. Figure 6C illustrates a model for ERK1/2 regulation of the NAG-1 promoter after isochaihulactone treatment. Treatment with the MAPK inhibitor PD98059 resulted in the reduction of NAG-1 promoter activity in the presence of isochaihulactone, thus supporting the hypothesis that isochaihulactone stimulates ERK1/2 activation and then induces ERG-1, which is required for expression of NAG-1.
In summary, we studied mechanisms underlying the antitumor activity of isochaihulactone because of our previous studies showing growth inhibition and antitumor activity in specific tumor cell lines in vitro and inhibition of a variety of xenografts including A549 lung cancer cell in vivo Chen et al., 2006) . cDNA microarray analysis a Genes listed were increased by Ն 1.5-fold a measured by Affymetrix GeneChip Software comparisons of isochaihulactone-treated versus vehicle-treated A549 cells.
showed that when A549 cells are exposed to isochaihulactone, NAG-1 is the most highly induced gene. ERK1/2 MAPK signaling pathways have been implicated in the regulation of Egr-1 and NAG-1 because isochaihulactone induces activation of phosphor-ERK in A549 cells. These results suggest a gene target for isochaihulactone, which may be useful for future clinical applications.
